Compare LKFN & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | LKFN | GENB |
|---|---|---|
| Founded | 1872 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2009 | 2026 |
| Metric | LKFN | GENB |
|---|---|---|
| Price | $62.49 | $15.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $67.00 | $23.20 |
| AVG Volume (30 Days) | 139.4K | ★ 476.8K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $985,000.00 | N/A |
| Revenue This Year | $15.50 | N/A |
| Revenue Next Year | $5.51 | $16.58 |
| P/E Ratio | $28.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.36 | $11.00 |
| 52 Week High | $69.38 | $18.18 |
| Indicator | LKFN | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 53.00 | 59.66 |
| Support Level | $57.90 | $11.82 |
| Resistance Level | $63.27 | $16.75 |
| Average True Range (ATR) | 1.15 | 0.84 |
| MACD | -0.08 | 0.18 |
| Stochastic Oscillator | 51.59 | 98.18 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.